Kolexia
Clement Karine
Endocrinologie
Hôpital Pitie Salpetriere
Paris, France
526 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Obésité Obésité morbide Inflammation Perte de poids Diabète de type 2 Insulinorésistance Fibrose Stéatose hépatique non alcoolique Stéatose hépatique

Industries

MSD
2 collaboration(s)
Dernière en 2023
Axis Santé
2 collaboration(s)
Dernière en 2023
Ipsen
1 collaboration(s)
Dernière en 2022
Biocodex
1 collaboration(s)
Dernière en 2020

Dernières activités

Role of IL-18 in adipose tissue remodeling and metabolic dysfunction.
International journal of obesity (2005)   08 mars 2024
Extracellular matrix hyaluronan modulates fat cell differentiation and primary cilia dynamics.
Biochimica et biophysica acta. Molecular and cell biology of lipids   28 février 2024
Hyperphagia and impulsivity: use of self-administered Dykens' and in-house impulsivity questionnaires to characterize eating behaviors in children with severe and early-onset obesity.
Orphanet journal of rare diseases   23 février 2024
Networks of gut bacteria relate to cardiovascular disease in a multi-ethnic population: the HELIUS study.
Cardiovascular research   30 janvier 2024
Nourishing the gut: the impact of diet on host-gut microbiota interaction.
Current opinion in clinical nutrition and metabolic care   18 janvier 2024
GUTERRING: Correcting GUT microbioTa by Combined Supplementation of fibERs and bIotiN to Improve Microbiome and Optimize Bariatric Surgery Outcomes
Essai Clinique (Assistance publique – Hôpitaux de Paris)   08 janvier 2024
DRIFTER: Fecal Microbiota Transfer to Improve Diabetes Control Post-bariatric Surgery
Essai Clinique (Assistance publique – Hôpitaux de Paris)   21 décembre 2023
Functional alterations and predictive capacity of gut microbiome in type 2 diabetes.
Scientific reports   16 décembre 2023
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity: A Phase 3 Trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity
Essai Clinique (Rhythm Pharmaceuticals, Inc.)   09 novembre 2023
Serum Versus Fecal Calprotectin Levels in Patients with Severe Obesity Before and 6 Months After Roux-Y-Gastric Bypass: Report of the Prospective Leaky-Gut Study.
Obesity surgery   04 novembre 2023